title: Response to Letter to the Editor From Drs. Stöllberger and Finsterer: Original Publication: "Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, and Safety of Apixaban".
authors.affiliation: Bristol-Myers Squibb, Princeton, NJ, USA.
authors.forename: Charles
authors.initials: C
authors.lastname: Frost
authors.affiliation: Bristol-Myers Squibb, Princeton, NJ, USA.
authors.forename: Ming
authors.initials: M
authors.lastname: Chang
authors.affiliation: Bristol-Myers Squibb, Princeton, NJ, USA.
authors.forename: Zhigang
authors.initials: Z
authors.lastname: Yu
authors.affiliation: Bristol-Myers Squibb, Princeton, NJ, USA.
authors.forename: Andrew
authors.initials: A
authors.lastname: Shenker
authors.affiliation: Bristol-Myers Squibb, Princeton, NJ, USA.
authors.forename: Jessie
authors.initials: J
authors.lastname: Wang
authors.affiliation: Bristol-Myers Squibb, Princeton, NJ, USA.
authors.forename: Janice
authors.initials: J
authors.lastname: Pursley
authors.affiliation: Pfizer Global Research & Development, Groton, CT, USA.
authors.forename: Wonkyung
authors.initials: W
authors.lastname: Byon
authors.affiliation: Pfizer Global Innovative Pharma Business, Groton, CT, USA.
authors.forename: Rebecca A
authors.initials: RA
authors.lastname: Boyd
authors.affiliation: Bristol-Myers Squibb, Princeton, NJ, USA.
authors.forename: Frank
authors.initials: F
authors.lastname: LaCreta
mesh_terms: D006801:Humans; D051437:Renal Insufficiency